CO5271668A1 - Derivados de purina - Google Patents
Derivados de purinaInfo
- Publication number
- CO5271668A1 CO5271668A1 CO01012091A CO01012091A CO5271668A1 CO 5271668 A1 CO5271668 A1 CO 5271668A1 CO 01012091 A CO01012091 A CO 01012091A CO 01012091 A CO01012091 A CO 01012091A CO 5271668 A1 CO5271668 A1 CO 5271668A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- fluoro
- alkoxy
- phenyl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
Abstract
Un compuesto de fórmula: <EMI FILE="01012091_1" ID="1" IMF=JPEG >o una de las sales o solvatos farmacéuticamente aceptables, en la que R1 es hidrógeno, alquilo C1-C6 o cicloalquilo, C3-C7, cada uno opcionalmente sustituido con 1 ó 2 sustituyentes seleccionados cada uno independientemente de hidroxilo fluorenilo, fenilo y naftilo, estando dicho fenilo y naftilo opcionalmente sustituidos con alquilo C1-C6 alcoxi C1-C6, halo o ciano;A es un enlace o alquileno C1-C6; R2 es (i) hidrógeno, alquilo C1-C6, cicloalquilo C3-C7, fenilo o naftilo, estando dichos cicloalquilo C3C7, fenilo y naftilo opcionalmente sustituidos con alquilo C1-C6, fenilo, (alcoxi C1-C6)(alquilo C1-C6), amino(alquilo C1-C6), fluoro(alquilo C1-C6), fluoro(alcoxi C1-C6), alcanoílo C2C5, halo, -OR3, ciano, -COOR3, cicloalquilo C3C7, -S(O)mR4, -NR3R3, -SO2NR3R3, -CONR3R3, -NR3COR4 o -NR3SO2R4, con la condición de que cuando A es un enlace, R2 no es hidrógeno,o (ii) cuando A es alquileno C2-C6, -NR3R3, -OR3, -COOR3, -OCOR4, -SO2R4, -CN, -SO2NR3R3, -NR3SO2R4, -NR3COR4 o -CONR3R3, o (iii) un heterociclo de 4 a 11 miembros unido por C que tiene de 1 a 4 átomos de nitrógeno en el anillo, o 1 ó 2 átomos de nitrógeno y 1 átomo de oxígeno o 1 átomo de azufre en el anillo, estando opcionalmente sustituido en C con oxo, (alcoxi C1-C6) (alquilo C1-C6), amino (alquilo C1-C6), fluoro(alquilo C1-C6) fluoro (alcoxi C1-C6), fluoro(alcanoilo C2-C5), halo, ciano, -OR5, R6, -COR5, NR5R5, COOR5, -S(O)mR6, -SO2NR5R5, -CONR5R5, -NR5SO2R6 o -NR5COR6 y opcionalmente sustitutido en N con (alcoxi C1-C6), (alquilo C1-C6), amino(alquilo C2-C6), fluoro(alquilo C1-C6), fluoro-(alcanoílo C2-C5), R6, -CR5, -COOR6, -SO2R6, -SO2NR5R5 o -CONR5R5 o (iv) cuando A es alquilo C2-C6, azetidinilo, pirrolidinilo, morfolinilo, tetrahidroisoquinolinilo, piperidinilo o piperazinilo unido por N, estando en cada uno opcionalmente sustituido en C con alquilo C1-C6, fenilo, (alcoxi C1-C6) (alquilo C1-C6), amino(alquilo C1-C6), fluoro(alquilo C1-C6), fluoro(alcoxi C1-C6), alcanoilo C2-C5, halo, -OR3, ciano, -COOR3, ciloalquilo C3-C7, -S(O)mR4, -NR3R3, -SO2NR3R3, -CONR3R3, -NR3COR4 o -NR3SO2R4, y estando dicho piperazinilo opcionalmente sustituido en N con alquilo C1-C6, fenilo, ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0003960.2A GB0003960D0 (en) | 2000-02-18 | 2000-02-18 | Purine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5271668A1 true CO5271668A1 (es) | 2003-04-30 |
Family
ID=9886026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01012091A CO5271668A1 (es) | 2000-02-18 | 2001-02-15 | Derivados de purina |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US6525032B2 (es) |
| EP (1) | EP1255764B8 (es) |
| JP (1) | JP2004508284A (es) |
| KR (1) | KR20030036138A (es) |
| CN (1) | CN1400975A (es) |
| AP (1) | AP2002002598A0 (es) |
| AR (1) | AR027437A1 (es) |
| AT (1) | ATE325807T1 (es) |
| AU (1) | AU2001230440A1 (es) |
| BG (1) | BG106906A (es) |
| BR (1) | BR0108408A (es) |
| CA (1) | CA2400619A1 (es) |
| CO (1) | CO5271668A1 (es) |
| CR (1) | CR6722A (es) |
| CZ (1) | CZ20022703A3 (es) |
| DE (1) | DE60119492T2 (es) |
| EA (1) | EA004987B1 (es) |
| EE (1) | EE200200452A (es) |
| ES (1) | ES2260199T3 (es) |
| GB (1) | GB0003960D0 (es) |
| GT (1) | GT200100027A (es) |
| HN (1) | HN2001000027A (es) |
| HR (1) | HRP20020676A2 (es) |
| HU (1) | HUP0301055A2 (es) |
| IL (1) | IL150543A0 (es) |
| IS (1) | IS6458A (es) |
| MA (1) | MA26873A1 (es) |
| MX (1) | MXPA02008068A (es) |
| NO (1) | NO20023894L (es) |
| NZ (1) | NZ519971A (es) |
| OA (1) | OA12177A (es) |
| PA (1) | PA8511801A1 (es) |
| PE (1) | PE20011122A1 (es) |
| PL (1) | PL357220A1 (es) |
| SK (1) | SK11692002A3 (es) |
| SV (1) | SV2002000317A (es) |
| TN (1) | TNSN01028A1 (es) |
| WO (1) | WO2001060835A1 (es) |
| ZA (1) | ZA200206526B (es) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| GB9913932D0 (en) * | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US6753322B2 (en) * | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
| US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| CA2460911C (en) * | 2001-10-01 | 2011-08-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| GB0129270D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Pharmaceutical combination |
| GB0129273D0 (en) | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Crystalline drug form |
| GB0129397D0 (en) * | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| US7423144B2 (en) | 2004-05-26 | 2008-09-09 | Inotek Pharmaceuticals Corporation | Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof |
| US7442687B2 (en) * | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| WO2006028618A1 (en) * | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| US7605143B2 (en) * | 2004-08-02 | 2009-10-20 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity |
| EP1802316B1 (en) * | 2004-09-20 | 2011-11-02 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR20080049113A (ko) | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Ｉｌ-13에 대항한 인간 항체 및 치료적 용도 |
| AU2006320578B2 (en) * | 2005-11-30 | 2013-01-31 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| WO2007092936A2 (en) * | 2006-02-08 | 2007-08-16 | University Of Virginia Patent Foundation | Method to treat gastric lesions |
| WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| ES2440317T3 (es) | 2006-04-21 | 2014-01-28 | Novartis Ag | Derivados de purina para su uso como agonistas del receptor de adenosina A2A |
| GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607951D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
| RU2009120389A (ru) | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Гетероциклические соединения в качестве противовоспалительных агентов |
| JP2008285478A (ja) * | 2007-04-16 | 2008-11-27 | Santen Pharmaceut Co Ltd | アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤 |
| US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
| UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| SI2391366T1 (sl) | 2009-01-29 | 2013-01-31 | Novartis Ag | Substituirani benzimidazoli za zdravljenje astrocitomov |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| CA2770873A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| SG178454A1 (en) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Heterocyclic compounds and uses thereof |
| IN2012DN01453A (es) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| CN102711771B (zh) | 2010-01-11 | 2016-05-18 | 伊诺泰克制药公司 | 降低眼压的组合、试剂盒和方法 |
| CN102933593A (zh) | 2010-03-26 | 2013-02-13 | 伊诺泰克制药公司 | 使用n6-环戊基腺苷（cpa）、cpa衍生物或其前药降低人眼内压的方法 |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
| CA2856803A1 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| EA027109B1 (ru) | 2012-01-26 | 2017-06-30 | Инотек Фармасьютикалс Корпорейшн | Безводные полиморфы [(2r,3s,4r,5r)-5-(6-(циклопентиламино)-9h-пурин-9-ил)-3,4-дигидрокситетрагидрофуран-2-ил]метилнитрата и способы их получения |
| EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
| MX2015013234A (es) | 2013-03-15 | 2016-04-15 | Inotek Pharmaceuticals Corp | Formulaciones oftalmicas. |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| EP3174541A1 (de) | 2014-07-28 | 2017-06-07 | Technische Universität Dresden | Thymin- und chinazolin-dion-derivate zur hemmung von hsp27 |
| AU2015294889B2 (en) | 2014-07-31 | 2018-03-15 | Novartis Ag | Combination therapy |
| TWI693594B (zh) * | 2015-03-13 | 2020-05-11 | 瑞典商杜比國際公司 | 解碼具有增強頻譜帶複製元資料在至少一填充元素中的音訊位元流 |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5140015A (en) * | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US5189027A (en) * | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
| IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| EP1121372B1 (en) * | 1998-10-16 | 2006-06-28 | Pfizer Limited | Adenine derivatives |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
-
2000
- 2000-02-18 GB GBGB0003960.2A patent/GB0003960D0/en not_active Ceased
-
2001
- 2001-02-09 AP APAP/P/2002/002598A patent/AP2002002598A0/en unknown
- 2001-02-09 JP JP2001560219A patent/JP2004508284A/ja active Pending
- 2001-02-09 CN CN01805069A patent/CN1400975A/zh active Pending
- 2001-02-09 PL PL01357220A patent/PL357220A1/xx not_active Application Discontinuation
- 2001-02-09 CZ CZ20022703A patent/CZ20022703A3/cs unknown
- 2001-02-09 EP EP01902583A patent/EP1255764B8/en not_active Expired - Lifetime
- 2001-02-09 ES ES01902583T patent/ES2260199T3/es not_active Expired - Lifetime
- 2001-02-09 EE EEP200200452A patent/EE200200452A/xx unknown
- 2001-02-09 BR BR0108408-9A patent/BR0108408A/pt not_active IP Right Cessation
- 2001-02-09 AU AU2001230440A patent/AU2001230440A1/en not_active Abandoned
- 2001-02-09 EA EA200200770A patent/EA004987B1/ru not_active IP Right Cessation
- 2001-02-09 WO PCT/IB2001/000167 patent/WO2001060835A1/en active IP Right Grant
- 2001-02-09 MX MXPA02008068A patent/MXPA02008068A/es active IP Right Grant
- 2001-02-09 AT AT01902583T patent/ATE325807T1/de not_active IP Right Cessation
- 2001-02-09 DE DE60119492T patent/DE60119492T2/de not_active Expired - Fee Related
- 2001-02-09 KR KR1020027010481A patent/KR20030036138A/ko active IP Right Grant
- 2001-02-09 HU HU0301055A patent/HUP0301055A2/hu unknown
- 2001-02-09 OA OA1200200250A patent/OA12177A/en unknown
- 2001-02-09 SK SK1169-2002A patent/SK11692002A3/sk unknown
- 2001-02-09 CA CA002400619A patent/CA2400619A1/en not_active Abandoned
- 2001-02-09 NZ NZ519971A patent/NZ519971A/en unknown
- 2001-02-09 IL IL15054301A patent/IL150543A0/xx unknown
- 2001-02-12 GT GT200100027A patent/GT200100027A/es unknown
- 2001-02-15 PA PA20018511801A patent/PA8511801A1/es unknown
- 2001-02-15 CO CO01012091A patent/CO5271668A1/es not_active Application Discontinuation
- 2001-02-15 HN HN2001000027A patent/HN2001000027A/es unknown
- 2001-02-15 AR ARP010100690A patent/AR027437A1/es not_active Application Discontinuation
- 2001-02-16 PE PE2001000174A patent/PE20011122A1/es not_active Application Discontinuation
- 2001-02-16 TN TNTNSN01028A patent/TNSN01028A1/fr unknown
- 2001-02-16 SV SV2001000317A patent/SV2002000317A/es not_active Application Discontinuation
- 2001-02-20 US US09/789,236 patent/US6525032B2/en not_active Expired - Fee Related
-
2002
- 2002-07-05 IS IS6458A patent/IS6458A/is unknown
- 2002-07-05 BG BG106906A patent/BG106906A/xx unknown
- 2002-08-06 CR CR6722A patent/CR6722A/es not_active Application Discontinuation
- 2002-08-12 MA MA26771A patent/MA26873A1/fr unknown
- 2002-08-15 ZA ZA200206526A patent/ZA200206526B/en unknown
- 2002-08-16 NO NO20023894A patent/NO20023894L/no not_active Application Discontinuation
- 2002-08-19 HR HRP20020676 patent/HRP20020676A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5271668A1 (es) | Derivados de purina | |
| CO5251399A1 (es) | Derivados de purina | |
| CO5261621A1 (es) | Derivados de purina | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
| TW334427B (en) | Preparation for diketopiperazines use as inhibitors of plasminogen activator inhibitor | |
| NO20062031L (no) | Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media | |
| HUP0102360A2 (hu) | 1,3-Oxazolin- és 1,3-tiazolin-származékok, eljárás a vegyületek előállítására és peszticidként történő alkalmazásuk | |
| TW370450B (en) | Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| WO2004000817A3 (en) | Benzimidazole compounds and their use as estrogen agonists/antagonists | |
| RS26604A (en) | Spiro-hydantoin compounds useful as anti-inflamatory agents | |
| ES2174757B1 (es) | Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares. | |
| IT1275433B (it) | Derivati di diarildiammine | |
| NZ332990A (en) | oral pharmaceutical composition containing a H+, K+-atpase inhibitor having a extended blood plasma profile | |
| NO20015446D0 (no) | Kinolin-derivater som inhibitorer for MEK-enzymer | |
| MX25770A (es) | Compuestos antidiabeticos y procedimientos para supreparacion. | |
| CA2013599A1 (en) | Aryl-substituted rhodanine derivatives | |
| CO5140116A1 (es) | Compuestos espiro derivados de imidazo-benzazepina con actividad antihistaminica y sus procesos de obtencion a partir de sus intermediarios de sintesis | |
| CO5611121A2 (es) | Derivados de fenil amidas con silicio utiles como microbicidas | |
| PH22994A (en) | New 6- or 7-methylenandrosta-1,4-diene-3,17-dione derivatives | |
| DK327286A (da) | Indolcarboxamidderivater og salte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter til deres fremstilling | |
| ATE192447T1 (de) | Camptothecin-derivate, ihre herstellung und antitumormittel | |
| DK1381370T3 (da) | N-Biphenylcarbonyl- og N-phenylpyridylcarbonyl-substituerede bi- og tricykliske azepiner og diazepiner som vasopressin-agonister | |
| CO4771143A1 (es) | Agentes insecticidas y acaricidas de 1,4-diaril-2-fluoro-2- buteno y proceso para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |